Opinion|Videos|November 25, 2024
VMS Symptoms and Neurokinin Receptor Antagonists
Panelists discuss how neurokinin 3 (NK3) receptors contribute to vasomotor symptoms (VMS) and how antagonism of NK3 receptors with drugs like fezolinetant can effectively reduce VMS, while also exploring the dual receptor action of elinzanetant, which blocks both NK1 and NK3 receptors to improve VMS and associated sleep disturbances.
Advertisement
Episodes in this series
- What are neurokinin 3 (NK3) receptors, and how can antagonism of NK3 receptors affect VMS?
- What is fezolinetant?
Note: The binding affinity of fezolinetant at NK3 receptors is 450 times greater than those for neurokinin 1 (NK1); this is an NK3 and has no NK1 action
- What is elinzanetant?
Note: Elinzanetant is currently under review with the FDA
- How can blockade of NK1 and NK3 receptors improve VMS and sleep disturbances associated with menopause?
Advertisement
Related to this article
Anita Nelson, MD, discusses the FDA's approval extending etonogestrel implant use to 5 years and the new REMS certification clinicians must complete by February 23, 2027.
Placentas from older mothers held less NAD+, and in aged pregnant mice, nicotinamide riboside or the CD38 inhibitor 78c restored placental NAD+ and improved fetal growth.
Hugh Taylor, MD, outlines a stepwise approach to endometriosis therapy, from first-line oral contraceptives to oral GnRH antagonists for progestin-resistant patients.
Hosted by Calbeth C. Alaribe, DMSc, MPH, PA-C, CPCHE, the monthly series brings clinicians, researchers, innovators, advocates, and other voices across women’s health into conversations that rarely happen in the same room.
A new book from Sameena Rahman, MD, reclaims "brown girls' disease" as a lens for examining how dismissal—of conditions, anatomy, and patients—undermines sexual medicine care for all women.
Menopause proteomics were consistently associated with inflammatory brain aging and Alzheimer’s dementia risk across nearly 15,000 women in a new study published in Nature Medicine.
The FDA approved an IDE allowing Mercy BioAnalytics to evaluate its Evident blood-based ovarian cancer screening test in the prospective pivotal SOARA study of average-risk women.
Sameena Rahman, MD, discusses how digital symptom trackers can shorten PMOS diagnostic delays and support earlier cardiometabolic care.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Q&A: Anita Nelson, MD, on etonogestrel implant's 5-year approval and REMS certification
2
Contemporary OB/GYN launches 'Missed & Dismissed' podcast to explore diagnostic gaps in women's health
3
Menopause proteomic scores associated with cognitive aging, dementia risk
4
CD38 is tied to age-related placental NAD+ decline in preclinical study
5